CTOs on the Move

Taro Pharmaceuticals (HQ)

www.tarousa.com

 
"Taro Pharmaceuticals U.S.A., Inc., and its divisions, subsidiaries and affiliates (collectively, ""Taro"") operate a variety of websites designed to provide you with services ranging from valuable health resources to corporate news and product information"
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.tarousa.com
  • 3 Skyline Dr Ste 120
    Hawthorne, NY USA 10532
  • Phone: 914.345.9001

Executives

Name Title Contact Details

Similar Companies

Impel Pharmaceuticals

Impel Pharmaceuticals specializes in Precision Olfactory Delivery (POD) nasal devices for Alzheimers, migraine, and other central nervous system diseases.

Panacea Pharmaceuticals

Panacea Pharmaceuticals is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vapotherm

Vapotherm Inc., is a publicly held corporation based in Exeter, New Hampshire that was founded in 1999 as a medical device manufacturer after creating the first heated and humidified high flow therapy nasal cannula system.

Cansortium

Cansortium Holdings utilizes a unique combination of capital and expertise in making strategic investments to help launch mature and professional cannabis markets. As global regulations evolve, Consortium Holdings is well-positioned to expand its presence in the U.S. and Puerto Rico.

Neurogastrx

We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.